LIDDS presence at BIO-Europe 2018 to focus on NanoZolid’s broad drug formulation capability

LIDDS presence at BIO-Europe 2018 to focus on NanoZolid’s broad drug formulation capability
1 November, 2018 admin.adstream

At BIO-Europe 2018, LIDDS will be meeting potential licensing and collaborative partners, to discuss the recently announced pre-clinical studies with NanoZolid-technology. The STING study is yet another proof point of NanoZolid’s ability to be formulated with a range of different drug molecules. BIO-Europe is one of the most important annual global partnering conferences for the pharmaceutical industry and is held in Copenhagen from November 5-7.

“At BIO-Europe we will be able to speak with potential licensing and collaborative partners on a range of opportunities, including the recently announced results from the NanoZolid®-STING agonist preclinical studies,” says Monica Wallter, CEO, LIDDS.

“We have shown that NanoZolid® can be formulated with a wide-range of active drug compounds. BIO-Europe offers an opportunity for LIDDS to further communicate to a global audience the broad formulation capability of NanoZolid®” says Monica Wallter.

NanoZolid® can be formulated with substances with very different molecular characteristics, and has been formulated with the following substances:

  • Anti-androgens: 2-hydroxy-flutamide & other anti-androgen drugs
  • Cytotoxic drugs: Docetaxel, Doxorubicin, Cisplatin, Temozolamide & other cytostatics
  • Immuno-active agents: STING-agonists, TLR- agonists, IDO1-inhibitors
  • Hormones: i.e Testosterone
  • Glucocorticoids
  • Antihistamines
  • Hormones
  • Polypeptides

When administered intratumorally, LIDDS NanoZolid® technology makes it possible to deliver a high drug load to cancer tumors without the side effects associated with traditional systemic anti-cancer treatments.

A subcutaneous injection of a NanoZolid® formulated drug can deliver active pharmaceuticals slowly and over an extended time period for effective systemic impact, reducing the number of injections or tablets required in many treatments and thereby improving patient compliance and quality of life.

LIDDS has ongoing clinical projects for prostate cancer in Phase IIb and several preclinical development projects for treating solid tumors with cytotoxic drugs and with STING-agonists.

For more information, please contact:
Monica Wallter, CEO LIDDS, +46 (0)737 07 09 22, monica.wallter@liddspharma.com  
                 
LIDDS AB (publ) is a Swedish-based pharmaceutical company with a unique drug delivery technology: NanoZolid®. NanoZolid is superior to any drug delivery technology in its ability to provide a controlled and sustained release of active drug substances for up to six months. LIDDS has licensing agreements where NanoZolid is combined with antiandrogens and in-house development projects in preclinical phase for cytostatics and immunoactive agents. LIDDS shares are listed on Nasdaq First North (LIDDS). For more information, please visit www.liddspharma.com